Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS -1.39%81 EV-to-EBIT is 19.64 as of Aug. 23, 2026, which is 35% above its 10-year median of 14.52. GuruFocus rates NSE:ALIVUS with a GF Score™ of 81/100 and a GF Value™ of ₹1,035.49 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 694 Drug Manufacturers companies, Alivus Life Sciences ranks worse than 58.21% on this metric.
Alivus Life Sciences (NSE:ALIVUS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alivus Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was ₹141,948 Mil.
Alivus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,060 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences EV-to-EBIT Related Terms
Alivus Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's EV-to-EBIT falls into.
Alivus Life Sciences's current Enterprise Value is ₹158,314 Mil.
Alivus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,060 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a EV-to-EBIT of 19.64 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alivus Life Sciences and its competitors. This is 35% above median its historical median of 14.52. Over the past decade, Alivus Life Sciences' EV-to-EBIT has ranged from 7.20 to 26.39. According to the industry distribution chart, Alivus Life Sciences ranks #404 out of 694 companies in the Drug Manufacturers industry, placing it in the top 58.2%.
Is Alivus Life Sciences' EV-to-EBIT too high?
Alivus Life Sciences' current EV-to-EBIT of 19.64 is 35% above median its 10-year median of 14.52. Over the past 10 years, this metric has ranged from a low of 7.20 to a high of 26.39. The Drug Manufacturers industry median EV-to-EBIT is 15.70. Alivus Life Sciences' value of 19.64 is 25.1% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #404 out of 694 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alivus Life Sciences has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #404 out of 694 companies for EV-to-EBIT. This places Alivus Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 15.70. Alivus Life Sciences' value of 19.64 is 25.1% above this benchmark. Historically, Alivus Life Sciences' own EV-to-EBIT has ranged from 7.20 to 26.39 over the past decade. While the company's 10-year median is 14.52 vs. the industry median of 15.70, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.70, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current EV-to-EBIT of 19.64 is 25.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current EV-to-EBIT is 19.64, which is 35% above median its own 10-year median of 14.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,035.49, compared to a current price of ₹1,350.90 — trading 30.5% above its estimated fair value. The current EV-to-EBIT is 19.64, which is 35% above median its 10-year median of 14.52 and 25.1% above the Drug Manufacturers industry median of 15.70. Alivus Life Sciences' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current EV-to-EBIT is 19.64 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,350.90 is trading 30.5% above its estimated GF Value™ of ₹1,035.49.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
EV-to-EBIT: 19.64 (35% above median its 10-year median of 14.52)
GF Value™: ₹1,035.49 vs. price of ₹1,350.90 (30.5% above fair value)
Industry Position: 25.1% above the Drug Manufacturers median (#404 of 694)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
81GF Score
Get the complete analysis for NSE:ALIVUS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
